| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pharmacogenetics | 43 | 2025 | 456 | 13.450 |
Why?
|
| Pharmacogenomic Testing | 16 | 2025 | 107 | 6.950 |
Why?
|
| Carcinoma, Transitional Cell | 23 | 2025 | 156 | 5.870 |
Why?
|
| Urologic Neoplasms | 19 | 2025 | 78 | 4.190 |
Why?
|
| Precision Medicine | 16 | 2025 | 454 | 3.830 |
Why?
|
| Urinary Bladder Neoplasms | 20 | 2025 | 382 | 3.280 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 7 | 2022 | 209 | 2.850 |
Why?
|
| Decision Support Systems, Clinical | 6 | 2025 | 123 | 2.580 |
Why?
|
| Drug Prescriptions | 6 | 2025 | 151 | 2.250 |
Why?
|
| Antineoplastic Agents | 24 | 2025 | 2418 | 2.180 |
Why?
|
| Cisplatin | 18 | 2024 | 611 | 2.040 |
Why?
|
| Prescription Drugs | 3 | 2025 | 39 | 2.020 |
Why?
|
| Pharmacogenomic Variants | 4 | 2021 | 44 | 2.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 14 | 2024 | 1021 | 1.830 |
Why?
|
| Antibodies, Monoclonal | 14 | 2024 | 1429 | 1.650 |
Why?
|
| Perioperative Care | 6 | 2022 | 188 | 1.650 |
Why?
|
| Antimetabolites, Antineoplastic | 7 | 2024 | 244 | 1.500 |
Why?
|
| Neoplasms | 12 | 2025 | 3248 | 1.440 |
Why?
|
| Immunoconjugates | 2 | 2022 | 131 | 1.380 |
Why?
|
| Humans | 126 | 2025 | 96112 | 1.350 |
Why?
|
| Biomarkers, Tumor | 8 | 2025 | 1670 | 1.340 |
Why?
|
| Clinical Decision-Making | 5 | 2021 | 296 | 1.330 |
Why?
|
| Capecitabine | 7 | 2024 | 99 | 1.280 |
Why?
|
| Patient Portals | 2 | 2020 | 22 | 1.260 |
Why?
|
| Decision Support Techniques | 2 | 2021 | 186 | 1.180 |
Why?
|
| Aged, 80 and over | 29 | 2025 | 7230 | 1.160 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2025 | 2494 | 1.150 |
Why?
|
| Anesthesiology | 2 | 2022 | 168 | 1.140 |
Why?
|
| Genotype | 11 | 2023 | 1882 | 1.130 |
Why?
|
| Aged | 47 | 2025 | 20972 | 1.130 |
Why?
|
| Middle Aged | 53 | 2025 | 28371 | 1.110 |
Why?
|
| Prospective Studies | 14 | 2025 | 4672 | 1.080 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2021 | 647 | 0.980 |
Why?
|
| Male | 57 | 2025 | 45871 | 0.980 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2020 | 296 | 0.960 |
Why?
|
| Adult | 43 | 2025 | 28725 | 0.930 |
Why?
|
| Female | 57 | 2025 | 50045 | 0.930 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2020 | 569 | 0.920 |
Why?
|
| Antineoplastic Agents, Immunological | 5 | 2024 | 225 | 0.890 |
Why?
|
| Genomics | 5 | 2022 | 857 | 0.890 |
Why?
|
| Cardiovascular Agents | 2 | 2015 | 61 | 0.880 |
Why?
|
| Urothelium | 5 | 2023 | 69 | 0.850 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 7 | 2016 | 944 | 0.830 |
Why?
|
| Point-of-Care Systems | 3 | 2019 | 155 | 0.760 |
Why?
|
| Patient Care Team | 1 | 2025 | 307 | 0.740 |
Why?
|
| Kidney Neoplasms | 5 | 2021 | 558 | 0.730 |
Why?
|
| Tramadol | 1 | 2022 | 14 | 0.730 |
Why?
|
| Hepatic Veno-Occlusive Disease | 2 | 2012 | 19 | 0.700 |
Why?
|
| Germ-Line Mutation | 4 | 2020 | 382 | 0.700 |
Why?
|
| Busulfan | 2 | 2012 | 43 | 0.700 |
Why?
|
| Anesthetics | 1 | 2021 | 56 | 0.680 |
Why?
|
| Pain Management | 2 | 2021 | 179 | 0.680 |
Why?
|
| Platinum | 5 | 2023 | 67 | 0.680 |
Why?
|
| B7-H1 Antigen | 9 | 2022 | 305 | 0.660 |
Why?
|
| Rheumatology | 1 | 2021 | 39 | 0.660 |
Why?
|
| Analgesics | 1 | 2021 | 132 | 0.650 |
Why?
|
| Anesthesia | 1 | 2022 | 175 | 0.630 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2021 | 367 | 0.620 |
Why?
|
| Medication Adherence | 1 | 2020 | 122 | 0.590 |
Why?
|
| Drug Labeling | 2 | 2017 | 42 | 0.580 |
Why?
|
| Information Dissemination | 1 | 2019 | 126 | 0.570 |
Why?
|
| Drug Therapy | 2 | 2018 | 70 | 0.560 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 777 | 0.560 |
Why?
|
| Pharmacology, Clinical | 1 | 2018 | 9 | 0.560 |
Why?
|
| Quinazolines | 2 | 2016 | 216 | 0.550 |
Why?
|
| Medical Order Entry Systems | 1 | 2017 | 27 | 0.520 |
Why?
|
| Germ Cells | 2 | 2022 | 134 | 0.520 |
Why?
|
| Inpatients | 3 | 2025 | 347 | 0.520 |
Why?
|
| Patient Care | 1 | 2018 | 101 | 0.510 |
Why?
|
| Follow-Up Studies | 11 | 2022 | 3927 | 0.510 |
Why?
|
| Vidarabine | 3 | 2012 | 146 | 0.500 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 513 | 0.500 |
Why?
|
| Fluorouracil | 2 | 2023 | 555 | 0.500 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2016 | 23 | 0.490 |
Why?
|
| Genome, Human | 3 | 2019 | 824 | 0.490 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 378 | 0.490 |
Why?
|
| Benzamides | 3 | 2024 | 248 | 0.490 |
Why?
|
| Receptor, ErbB-3 | 1 | 2016 | 19 | 0.490 |
Why?
|
| Critical Care | 1 | 2019 | 447 | 0.470 |
Why?
|
| Physician-Patient Relations | 2 | 2019 | 635 | 0.460 |
Why?
|
| Physician's Role | 1 | 2017 | 186 | 0.460 |
Why?
|
| Quality of Life | 7 | 2024 | 1816 | 0.460 |
Why?
|
| Clinical Medicine | 1 | 2015 | 34 | 0.460 |
Why?
|
| Cytochrome P-450 CYP2D6 | 3 | 2022 | 52 | 0.460 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2015 | 81 | 0.460 |
Why?
|
| Clinical Trials, Phase II as Topic | 4 | 2014 | 172 | 0.460 |
Why?
|
| Collagen Type I | 1 | 2015 | 74 | 0.450 |
Why?
|
| Snake Venoms | 2 | 2015 | 9 | 0.450 |
Why?
|
| Patient Selection | 3 | 2018 | 709 | 0.450 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2025 | 2474 | 0.440 |
Why?
|
| Academic Medical Centers | 2 | 2015 | 422 | 0.430 |
Why?
|
| Programmed Cell Death 1 Receptor | 5 | 2022 | 188 | 0.430 |
Why?
|
| Pyrroles | 2 | 2015 | 172 | 0.430 |
Why?
|
| Receptor, ErbB-2 | 1 | 2016 | 280 | 0.420 |
Why?
|
| Transplantation Conditioning | 4 | 2014 | 383 | 0.410 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 2642 | 0.400 |
Why?
|
| Cardiology | 1 | 2015 | 130 | 0.400 |
Why?
|
| Inflammation | 1 | 2019 | 1068 | 0.400 |
Why?
|
| Indoles | 2 | 2015 | 317 | 0.400 |
Why?
|
| Ambulatory Care | 2 | 2014 | 198 | 0.400 |
Why?
|
| Program Development | 1 | 2014 | 136 | 0.400 |
Why?
|
| Neovascularization, Pathologic | 1 | 2015 | 354 | 0.400 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2012 | 21 | 0.380 |
Why?
|
| Nectins | 2 | 2022 | 9 | 0.380 |
Why?
|
| Hematologic Neoplasms | 4 | 2016 | 372 | 0.380 |
Why?
|
| Pain | 4 | 2024 | 426 | 0.370 |
Why?
|
| Stomach Neoplasms | 1 | 2015 | 310 | 0.370 |
Why?
|
| Mutation | 6 | 2020 | 4374 | 0.370 |
Why?
|
| Young Adult | 7 | 2025 | 7025 | 0.370 |
Why?
|
| Cystectomy | 2 | 2024 | 114 | 0.360 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 611 | 0.360 |
Why?
|
| Peptides | 1 | 2015 | 672 | 0.360 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2024 | 286 | 0.350 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2024 | 1973 | 0.350 |
Why?
|
| Pharmaceutical Preparations | 1 | 2012 | 97 | 0.340 |
Why?
|
| Neoplasm Staging | 7 | 2021 | 2086 | 0.340 |
Why?
|
| Kidney Failure, Chronic | 2 | 2016 | 432 | 0.340 |
Why?
|
| Patient Safety | 4 | 2023 | 223 | 0.340 |
Why?
|
| Deoxycytidine | 1 | 2012 | 216 | 0.330 |
Why?
|
| Cell Adhesion Molecules | 2 | 2022 | 176 | 0.330 |
Why?
|
| Prognosis | 12 | 2020 | 4029 | 0.330 |
Why?
|
| Treatment Outcome | 18 | 2024 | 9176 | 0.330 |
Why?
|
| Antibodies, Neoplasm | 1 | 2010 | 86 | 0.330 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 198 | 0.320 |
Why?
|
| Hemoglobinopathies | 1 | 2010 | 9 | 0.320 |
Why?
|
| Carcinoma | 3 | 2021 | 448 | 0.320 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 1471 | 0.320 |
Why?
|
| Neoplasm Metastasis | 7 | 2024 | 1094 | 0.310 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2011 | 644 | 0.310 |
Why?
|
| Kidney Medulla | 1 | 2010 | 80 | 0.310 |
Why?
|
| BK Virus | 1 | 2009 | 24 | 0.310 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 855 | 0.300 |
Why?
|
| Polyomavirus Infections | 1 | 2009 | 29 | 0.300 |
Why?
|
| Pyrimidines | 3 | 2018 | 386 | 0.300 |
Why?
|
| Hematuria | 1 | 2009 | 50 | 0.300 |
Why?
|
| Tumor Virus Infections | 1 | 2009 | 83 | 0.300 |
Why?
|
| Carboplatin | 6 | 2016 | 331 | 0.300 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 2 | 2024 | 111 | 0.300 |
Why?
|
| Breast Neoplasms | 2 | 2020 | 3157 | 0.290 |
Why?
|
| Genetic Testing | 4 | 2019 | 565 | 0.290 |
Why?
|
| Warfarin | 2 | 2019 | 107 | 0.280 |
Why?
|
| Disease Susceptibility | 1 | 2009 | 220 | 0.280 |
Why?
|
| Genetic Variation | 3 | 2014 | 1423 | 0.280 |
Why?
|
| Anemia, Sickle Cell | 1 | 2010 | 150 | 0.270 |
Why?
|
| Risk Assessment | 3 | 2021 | 2480 | 0.270 |
Why?
|
| Surveys and Questionnaires | 3 | 2020 | 2860 | 0.260 |
Why?
|
| Models, Genetic | 1 | 2012 | 984 | 0.260 |
Why?
|
| Kidney Diseases | 1 | 2009 | 325 | 0.250 |
Why?
|
| Urinary Bladder | 3 | 2024 | 263 | 0.250 |
Why?
|
| Cohort Studies | 4 | 2019 | 3110 | 0.240 |
Why?
|
| Risk Factors | 5 | 2021 | 5961 | 0.240 |
Why?
|
| Genotyping Techniques | 2 | 2018 | 71 | 0.240 |
Why?
|
| Transplantation, Homologous | 7 | 2020 | 1023 | 0.240 |
Why?
|
| Kidney | 1 | 2011 | 1156 | 0.230 |
Why?
|
| Sirolimus | 1 | 2006 | 177 | 0.230 |
Why?
|
| Neoplasm Invasiveness | 6 | 2024 | 580 | 0.230 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2019 | 935 | 0.230 |
Why?
|
| United States | 6 | 2025 | 7768 | 0.220 |
Why?
|
| Neuroendocrine Tumors | 1 | 2006 | 136 | 0.220 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2025 | 91 | 0.210 |
Why?
|
| Polymorphism, Genetic | 3 | 2015 | 829 | 0.210 |
Why?
|
| Tertiary Care Centers | 2 | 2016 | 128 | 0.210 |
Why?
|
| Phenylthiohydantoin | 1 | 2024 | 48 | 0.210 |
Why?
|
| Medical Oncology | 2 | 2022 | 408 | 0.210 |
Why?
|
| Nitriles | 1 | 2024 | 157 | 0.210 |
Why?
|
| Survival Analysis | 6 | 2023 | 1546 | 0.200 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2016 | 299 | 0.200 |
Why?
|
| Insurance Coverage | 1 | 2025 | 144 | 0.200 |
Why?
|
| Adolescent | 8 | 2025 | 9895 | 0.200 |
Why?
|
| Insurance, Health | 1 | 2025 | 182 | 0.200 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2024 | 53 | 0.200 |
Why?
|
| Neutropenia | 1 | 2023 | 218 | 0.200 |
Why?
|
| Proprotein Convertase 9 | 1 | 2023 | 27 | 0.190 |
Why?
|
| Alemtuzumab | 3 | 2012 | 90 | 0.190 |
Why?
|
| Adenine Nucleotides | 2 | 2014 | 63 | 0.190 |
Why?
|
| Arabinonucleosides | 2 | 2014 | 39 | 0.190 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2023 | 87 | 0.190 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2024 | 144 | 0.190 |
Why?
|
| Hospitalization | 2 | 2019 | 943 | 0.190 |
Why?
|
| Genome-Wide Association Study | 8 | 2025 | 1765 | 0.190 |
Why?
|
| Thrombocytopenia | 1 | 2023 | 191 | 0.190 |
Why?
|
| Chicago | 5 | 2015 | 1506 | 0.190 |
Why?
|
| Fenretinide | 1 | 2002 | 2 | 0.190 |
Why?
|
| Omeprazole | 1 | 2022 | 11 | 0.190 |
Why?
|
| Succinylcholine | 1 | 2022 | 14 | 0.190 |
Why?
|
| Ceramides | 1 | 2002 | 36 | 0.190 |
Why?
|
| Hydralazine | 1 | 2022 | 21 | 0.180 |
Why?
|
| Serine Endopeptidases | 1 | 2023 | 150 | 0.180 |
Why?
|
| Sulfonamides | 2 | 2016 | 337 | 0.180 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2024 | 190 | 0.180 |
Why?
|
| Oxycodone | 1 | 2022 | 35 | 0.180 |
Why?
|
| Lymphocytes | 3 | 2010 | 489 | 0.180 |
Why?
|
| Patient Readmission | 1 | 2025 | 413 | 0.170 |
Why?
|
| Muscles | 1 | 2021 | 193 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 1096 | 0.160 |
Why?
|
| Ferredoxin-NADP Reductase | 1 | 2020 | 15 | 0.160 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 28 | 0.160 |
Why?
|
| Disease-Free Survival | 6 | 2021 | 1196 | 0.160 |
Why?
|
| Pyrazines | 1 | 2020 | 94 | 0.160 |
Why?
|
| Research | 2 | 2019 | 265 | 0.160 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2022 | 187 | 0.150 |
Why?
|
| Clinical Trials as Topic | 2 | 2016 | 1179 | 0.150 |
Why?
|
| Drug Recalls | 1 | 2019 | 12 | 0.150 |
Why?
|
| Codeine | 1 | 2019 | 12 | 0.150 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 65 | 0.150 |
Why?
|
| CREB-Binding Protein | 1 | 2018 | 16 | 0.150 |
Why?
|
| Phenotype | 3 | 2019 | 2579 | 0.150 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2018 | 15 | 0.150 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 1807 | 0.150 |
Why?
|
| Survival Rate | 3 | 2018 | 1985 | 0.150 |
Why?
|
| Pilot Projects | 2 | 2019 | 938 | 0.150 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 458 | 0.140 |
Why?
|
| Acute Kidney Injury | 2 | 2014 | 342 | 0.140 |
Why?
|
| Electronic Health Records | 2 | 2025 | 372 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2021 | 1346 | 0.140 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 4 | 2021 | 60 | 0.140 |
Why?
|
| Tumor Burden | 1 | 2019 | 322 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2019 | 323 | 0.140 |
Why?
|
| Infusions, Intravenous | 3 | 2017 | 423 | 0.140 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 555 | 0.140 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2002 | 423 | 0.140 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 169 | 0.140 |
Why?
|
| Vinca Alkaloids | 2 | 2025 | 4 | 0.140 |
Why?
|
| Radiosurgery | 1 | 2021 | 316 | 0.140 |
Why?
|
| Abdominal Neoplasms | 1 | 2017 | 40 | 0.130 |
Why?
|
| Standard of Care | 1 | 2017 | 70 | 0.130 |
Why?
|
| Pain, Postoperative | 1 | 2019 | 277 | 0.130 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 157 | 0.130 |
Why?
|
| Health Personnel | 1 | 2019 | 241 | 0.120 |
Why?
|
| Organoplatinum Compounds | 2 | 2019 | 100 | 0.120 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 2016 | 7 | 0.120 |
Why?
|
| Disease Management | 1 | 2019 | 360 | 0.120 |
Why?
|
| Social Perception | 1 | 2017 | 94 | 0.120 |
Why?
|
| Tissue Donors | 1 | 2020 | 542 | 0.120 |
Why?
|
| User-Computer Interface | 1 | 2017 | 196 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2024 | 518 | 0.120 |
Why?
|
| Safety | 1 | 2017 | 147 | 0.120 |
Why?
|
| Hospital Mortality | 1 | 2019 | 483 | 0.120 |
Why?
|
| Anticoagulants | 1 | 2019 | 463 | 0.120 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 328 | 0.120 |
Why?
|
| Benzodioxoles | 1 | 2015 | 15 | 0.120 |
Why?
|
| Liver | 3 | 2022 | 1238 | 0.120 |
Why?
|
| Attitude to Health | 1 | 2017 | 226 | 0.120 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1958 | 0.120 |
Why?
|
| Universities | 2 | 2013 | 154 | 0.120 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2015 | 58 | 0.110 |
Why?
|
| Transcription Factor RelA | 1 | 2015 | 49 | 0.110 |
Why?
|
| Immunotherapy | 2 | 2020 | 766 | 0.110 |
Why?
|
| 5' Untranslated Regions | 1 | 2015 | 54 | 0.110 |
Why?
|
| Forecasting | 1 | 2016 | 317 | 0.110 |
Why?
|
| Communication | 1 | 2019 | 477 | 0.110 |
Why?
|
| G(M2) Ganglioside | 1 | 2015 | 3 | 0.110 |
Why?
|
| Survivors | 1 | 2016 | 204 | 0.110 |
Why?
|
| Tay-Sachs Disease | 1 | 2015 | 6 | 0.110 |
Why?
|
| Response Elements | 1 | 2015 | 65 | 0.110 |
Why?
|
| Tunica Intima | 1 | 2015 | 61 | 0.110 |
Why?
|
| Area Under Curve | 2 | 2014 | 340 | 0.110 |
Why?
|
| Fatal Outcome | 1 | 2015 | 304 | 0.110 |
Why?
|
| Ureter | 1 | 2016 | 96 | 0.110 |
Why?
|
| Epilepsies, Myoclonic | 1 | 2015 | 21 | 0.110 |
Why?
|
| Maximum Tolerated Dose | 2 | 2017 | 271 | 0.110 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 682 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 1 | 2016 | 312 | 0.110 |
Why?
|
| Kidney Transplantation | 2 | 2016 | 882 | 0.110 |
Why?
|
| Nomograms | 1 | 2014 | 35 | 0.110 |
Why?
|
| Exome | 1 | 2014 | 141 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 667 | 0.100 |
Why?
|
| Liver Neoplasms | 2 | 2017 | 793 | 0.100 |
Why?
|
| Genetic Markers | 1 | 2014 | 479 | 0.100 |
Why?
|
| Radiography | 1 | 2015 | 826 | 0.100 |
Why?
|
| Total Quality Management | 1 | 2013 | 34 | 0.100 |
Why?
|
| Software | 1 | 2017 | 698 | 0.100 |
Why?
|
| Receptors, Cell Surface | 1 | 2014 | 298 | 0.100 |
Why?
|
| Muscle Neoplasms | 1 | 2013 | 17 | 0.100 |
Why?
|
| Endothelium, Vascular | 1 | 2015 | 437 | 0.100 |
Why?
|
| Endonucleases | 1 | 2012 | 23 | 0.100 |
Why?
|
| Workflow | 1 | 2013 | 80 | 0.100 |
Why?
|
| Fanconi Anemia | 1 | 2012 | 9 | 0.100 |
Why?
|
| Genetics, Medical | 1 | 2013 | 51 | 0.100 |
Why?
|
| DNA Repair | 1 | 2014 | 376 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 1 | 2016 | 449 | 0.090 |
Why?
|
| Biopsy | 2 | 2016 | 1220 | 0.090 |
Why?
|
| Lymphocyte Depletion | 1 | 2012 | 101 | 0.090 |
Why?
|
| Delivery of Health Care | 1 | 2017 | 469 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2016 | 594 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2022 | 540 | 0.090 |
Why?
|
| Atherosclerosis | 1 | 2015 | 271 | 0.090 |
Why?
|
| Blood Glucose | 1 | 2016 | 873 | 0.090 |
Why?
|
| Combined Modality Therapy | 3 | 2024 | 1773 | 0.090 |
Why?
|
| Disease Progression | 3 | 2016 | 1564 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2016 | 1010 | 0.090 |
Why?
|
| Biomedical Research | 2 | 2013 | 441 | 0.090 |
Why?
|
| Time Factors | 3 | 2016 | 5585 | 0.090 |
Why?
|
| Graft vs Host Disease | 2 | 2012 | 368 | 0.090 |
Why?
|
| Fibroblasts | 1 | 2015 | 777 | 0.090 |
Why?
|
| Decision Making | 1 | 2017 | 694 | 0.090 |
Why?
|
| Melphalan | 1 | 2011 | 100 | 0.090 |
Why?
|
| T-Lymphocytes | 2 | 2022 | 1316 | 0.090 |
Why?
|
| HLA Antigens | 1 | 2012 | 231 | 0.080 |
Why?
|
| Population Groups | 1 | 2010 | 42 | 0.080 |
Why?
|
| Metabolic Clearance Rate | 1 | 2010 | 119 | 0.080 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 193 | 0.080 |
Why?
|
| Chromosomes, Human, X | 1 | 2011 | 57 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2012 | 218 | 0.080 |
Why?
|
| Graft Rejection | 2 | 2016 | 1126 | 0.080 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2010 | 64 | 0.080 |
Why?
|
| Drug Combinations | 1 | 2010 | 214 | 0.080 |
Why?
|
| Cell Line, Transformed | 1 | 2010 | 156 | 0.080 |
Why?
|
| Cell Line | 5 | 2011 | 2537 | 0.080 |
Why?
|
| Postoperative Complications | 2 | 2016 | 2591 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 465 | 0.080 |
Why?
|
| Anthracyclines | 1 | 2009 | 38 | 0.080 |
Why?
|
| Down-Regulation | 1 | 2010 | 526 | 0.070 |
Why?
|
| DNA | 1 | 2014 | 1333 | 0.070 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2009 | 138 | 0.070 |
Why?
|
| Haplotypes | 1 | 2010 | 650 | 0.070 |
Why?
|
| Creatinine | 1 | 2009 | 299 | 0.070 |
Why?
|
| Immune Complex Diseases | 1 | 2008 | 20 | 0.070 |
Why?
|
| Neutrophil Infiltration | 1 | 2008 | 33 | 0.070 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2008 | 76 | 0.070 |
Why?
|
| Cell Proliferation | 2 | 2010 | 1755 | 0.070 |
Why?
|
| Genetics, Population | 1 | 2010 | 437 | 0.060 |
Why?
|
| Fatigue | 2 | 2022 | 185 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 1267 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 771 | 0.060 |
Why?
|
| Neurons | 1 | 2015 | 1653 | 0.060 |
Why?
|
| Incidence | 1 | 2010 | 1715 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 995 | 0.060 |
Why?
|
| Bridged-Ring Compounds | 1 | 2025 | 16 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2017 | 873 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 3 | 2022 | 3490 | 0.060 |
Why?
|
| Kidney Function Tests | 2 | 2016 | 119 | 0.060 |
Why?
|
| Taxoids | 1 | 2025 | 131 | 0.050 |
Why?
|
| Ovarian Neoplasms | 1 | 2011 | 801 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 713 | 0.050 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2024 | 20 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 3652 | 0.050 |
Why?
|
| Indazoles | 2 | 2016 | 61 | 0.050 |
Why?
|
| Models, Biological | 1 | 2011 | 1810 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2011 | 1089 | 0.050 |
Why?
|
| Receptors, Androgen | 1 | 2024 | 120 | 0.050 |
Why?
|
| Hyperparathyroidism | 1 | 2003 | 65 | 0.050 |
Why?
|
| Dihydrouracil Dehydrogenase (NADP) | 1 | 2023 | 28 | 0.050 |
Why?
|
| Asialoglycoprotein Receptor | 1 | 2023 | 2 | 0.050 |
Why?
|
| Proprotein Convertases | 1 | 2023 | 27 | 0.050 |
Why?
|
| Leucine | 1 | 2022 | 62 | 0.050 |
Why?
|
| Parathyroidectomy | 1 | 2003 | 79 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 884 | 0.050 |
Why?
|
| Pharmacists | 1 | 2022 | 36 | 0.050 |
Why?
|
| Cell Line, Tumor | 3 | 2016 | 2778 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 2 | 2016 | 289 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2014 | 156 | 0.050 |
Why?
|
| Alleles | 2 | 2017 | 1157 | 0.050 |
Why?
|
| Adrenal Insufficiency | 1 | 2022 | 24 | 0.050 |
Why?
|
| Sphingolipids | 1 | 2002 | 22 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 60 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 2883 | 0.050 |
Why?
|
| Morpholines | 1 | 2002 | 77 | 0.050 |
Why?
|
| Age Factors | 2 | 2020 | 1963 | 0.040 |
Why?
|
| Diet, High-Fat | 1 | 2022 | 135 | 0.040 |
Why?
|
| Antibody Formation | 1 | 2022 | 181 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2002 | 317 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2022 | 191 | 0.040 |
Why?
|
| Ligands | 1 | 2023 | 478 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2023 | 246 | 0.040 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2022 | 164 | 0.040 |
Why?
|
| DNA Damage | 1 | 2023 | 392 | 0.040 |
Why?
|
| Gene Fusion | 1 | 2021 | 40 | 0.040 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2021 | 60 | 0.040 |
Why?
|
| beta Catenin | 1 | 2022 | 266 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2024 | 10287 | 0.040 |
Why?
|
| Hodgkin Disease | 1 | 2001 | 170 | 0.040 |
Why?
|
| Cholesterol | 1 | 2022 | 370 | 0.040 |
Why?
|
| Risk | 2 | 2012 | 668 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2001 | 294 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 1049 | 0.040 |
Why?
|
| Blood Transfusion | 1 | 2001 | 182 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 1798 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 348 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 311 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 303 | 0.040 |
Why?
|
| Cell Survival | 1 | 2002 | 1030 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2023 | 1791 | 0.040 |
Why?
|
| Allografts | 1 | 2020 | 207 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2020 | 183 | 0.040 |
Why?
|
| Gene Expression | 2 | 2015 | 1320 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2019 | 156 | 0.040 |
Why?
|
| Mice | 3 | 2022 | 12541 | 0.030 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2018 | 107 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 684 | 0.030 |
Why?
|
| Retreatment | 1 | 2017 | 106 | 0.030 |
Why?
|
| Internationality | 1 | 2017 | 76 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2017 | 162 | 0.030 |
Why?
|
| BCG Vaccine | 1 | 2017 | 38 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2018 | 336 | 0.030 |
Why?
|
| Social Discrimination | 1 | 2016 | 7 | 0.030 |
Why?
|
| Remission Induction | 1 | 2018 | 769 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 547 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2017 | 137 | 0.030 |
Why?
|
| Employment | 1 | 2016 | 57 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2016 | 84 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2016 | 70 | 0.030 |
Why?
|
| Child | 3 | 2016 | 7625 | 0.030 |
Why?
|
| Europe | 1 | 2016 | 349 | 0.030 |
Why?
|
| Cholesterol, Dietary | 1 | 2015 | 27 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2018 | 432 | 0.030 |
Why?
|
| Transplants | 1 | 2016 | 43 | 0.030 |
Why?
|
| E-Selectin | 1 | 2015 | 31 | 0.030 |
Why?
|
| Carotid Artery Injuries | 1 | 2015 | 22 | 0.030 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2015 | 40 | 0.030 |
Why?
|
| Receptors, LDL | 1 | 2015 | 54 | 0.030 |
Why?
|
| Glycoside Hydrolase Inhibitors | 1 | 2015 | 1 | 0.030 |
Why?
|
| 1-Deoxynojirimycin | 1 | 2015 | 3 | 0.030 |
Why?
|
| RNA Polymerase II | 1 | 2015 | 62 | 0.030 |
Why?
|
| Netrin Receptors | 1 | 2014 | 7 | 0.030 |
Why?
|
| Protein Interaction Mapping | 1 | 2015 | 81 | 0.030 |
Why?
|
| Lentivirus | 1 | 2015 | 44 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 688 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2016 | 181 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2015 | 83 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2016 | 157 | 0.030 |
Why?
|
| Microsomes, Liver | 1 | 2014 | 49 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2015 | 162 | 0.030 |
Why?
|
| Transgenes | 1 | 2015 | 186 | 0.030 |
Why?
|
| Recurrence | 2 | 2011 | 1218 | 0.030 |
Why?
|
| Social Support | 1 | 2016 | 239 | 0.030 |
Why?
|
| Plasmids | 1 | 2015 | 291 | 0.030 |
Why?
|
| Reference Standards | 1 | 2014 | 150 | 0.030 |
Why?
|
| Ireland | 1 | 2013 | 12 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 393 | 0.030 |
Why?
|
| Nephrectomy | 1 | 2016 | 297 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2017 | 644 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2015 | 446 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2015 | 182 | 0.020 |
Why?
|
| Animals | 3 | 2022 | 28919 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2013 | 183 | 0.020 |
Why?
|
| Transplantation Chimera | 1 | 2012 | 84 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2015 | 480 | 0.020 |
Why?
|
| Graft Survival | 1 | 2016 | 942 | 0.020 |
Why?
|
| United States Department of Defense | 1 | 2011 | 4 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 1829 | 0.020 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2011 | 15 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 996 | 0.020 |
Why?
|
| Students | 1 | 2013 | 179 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2015 | 515 | 0.020 |
Why?
|
| Orchiectomy | 1 | 2011 | 63 | 0.020 |
Why?
|
| Contrast Media | 1 | 2016 | 1097 | 0.020 |
Why?
|
| Transplantation, Autologous | 2 | 2003 | 362 | 0.020 |
Why?
|
| Action Potentials | 1 | 2015 | 618 | 0.020 |
Why?
|
| Insulin | 1 | 2016 | 1190 | 0.020 |
Why?
|
| Computational Biology | 1 | 2014 | 586 | 0.020 |
Why?
|
| Genes, X-Linked | 1 | 2011 | 39 | 0.020 |
Why?
|
| Diarrhea | 1 | 2011 | 181 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2015 | 1192 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 901 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2015 | 2161 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2011 | 239 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2015 | 2940 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2011 | 271 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2010 | 126 | 0.020 |
Why?
|
| Laparoscopy | 1 | 2016 | 784 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2010 | 329 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2013 | 502 | 0.020 |
Why?
|
| Macrophage-1 Antigen | 1 | 2008 | 18 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 1981 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 553 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2015 | 1667 | 0.020 |
Why?
|
| Receptors, IgG | 1 | 2008 | 68 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2016 | 1230 | 0.020 |
Why?
|
| Registries | 1 | 2013 | 986 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2008 | 279 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2008 | 433 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2015 | 1730 | 0.020 |
Why?
|
| Physicians | 1 | 2013 | 707 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 1535 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2011 | 841 | 0.010 |
Why?
|
| Biomarkers | 1 | 2011 | 1932 | 0.010 |
Why?
|
| Baltimore | 1 | 2001 | 43 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2001 | 1176 | 0.010 |
Why?
|